Massachusetts General Hospital researchers engineered IFN-γ-resistant CD28 CAR-T cells that partially evade activation-induced cell death, enhancing survival and anti-tumor efficacy in multiple murine solid tumor models. The modified CAR-T cells demonstrate increased durability and activity, addressing a major limitation in treating solid tumors. The findings, published in Science Translational Medicine, suggest potential for improved CAR-T therapies in oncology.